» Articles » PMID: 27456700

Evaluation of Potential Drug- Drug Interactions Among Palestinian Hemodialysis Patients

Overview
Journal BMC Nephrol
Publisher Biomed Central
Specialty Nephrology
Date 2016 Jul 27
PMID 27456700
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients with Hemodialysis and identify factors associated with these interactions if present.

Methods: The study was an observational- retrospective cohort study that was conducted in ten hemodialysis units in the West bank, Palestine, between June and August 2015. The data collection form was completed by interviewing the patients in addition to reviewing their medical records. Potential DDIs were reviewed. SPSS program was used for data analysis.

Results: The study included 275 patients, a total of 930 potential interactions were identified in 245 (89.1 %) patients. Patients were prescribed 1-15 drugs with a mean (± SD) of 7.87 ± 2.44, calcium carbonate was the most common drug prescribed. The most common potential interaction in 114 (41.5 %) patients was Calcium Carbonate/Amlodipine followed by Calcium Carbonate/Aspirin in 76 (27.6 %) cases. Most patients (89.9 %) of the patients had one or more comorbid diseases; hypertension, diabetes and gout were the most common. Univariate analysis showed that the number of potential DDIs were related to the number of diseases, the number of prescribed drugs (P value <0.0001) and the age of the patient (P value = 0.015). The results of multiple linear regression showed a significant positive association between number of potential DDIs with the total number of medications (r = 0.242; p < 0.001).

Conclusion: The prevalence of potential drug- drug interactions among hemodialysis patients is very common; they are highly expected and depend on the number of drugs taken by the patients. Many of these potential interactions are considered as preventable drug- related problems, so screening for potential interactions and monitoring regularly is highly needed.

Citing Articles

Impact of pharmacist-led medication review among hemodialysis patients: a systematic review.

Paneerselvam G, Kah Yee C, Farrukh M, Yuda A, Hermansyah A, Mohd Asmani M J Pharm Policy Pract. 2025; 18(1):2446912.

PMID: 39911588 PMC: 11795745. DOI: 10.1080/20523211.2024.2446912.


Drug utilisation study in hospitalised chronic kidney disease patients, using World Health Organisation prescribing indicators: an observational study.

Alruqayb W, Paudyal V, Malcolm P, Sarwar A, Aston J, Cox A J Pharm Policy Pract. 2024; 17(1):2430436.

PMID: 39640417 PMC: 11619015. DOI: 10.1080/20523211.2024.2430436.


An Assessment of Different Decision Support Software from the Perspective of Potential Drug-Drug Interactions in Patients with Chronic Kidney Diseases.

Bektay M, Buker Cakir A, Gursu M, Kazancioglu R, Izzettin F Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794132 PMC: 11124126. DOI: 10.3390/ph17050562.


Clinical Pertinence and Determinants of Potential Drug-Drug Interactions in Chronic Kidney Disease Patients: A Cross-sectional Study.

Khanna J, Kumar S, Mehta S, Chaudhary J, Jain A J Pharm Technol. 2024; 40(3):142-151.

PMID: 38784027 PMC: 11110732. DOI: 10.1177/87551225241241977.


A multicenter descriptive analysis of anemia management in hemodialysis patients and its association with quality of life.

Al-Jabi S, Rajabi N, Koni A, Zyoud S BMC Nephrol. 2023; 24(1):197.

PMID: 37391687 PMC: 10314542. DOI: 10.1186/s12882-023-03254-7.


References
1.
Huang C, Chan W, Chen Y, Chen T, Chung C, Huang P . The beneficial effects of statins in patients undergoing hemodialysis. Int J Cardiol. 2013; 168(4):4155-9. DOI: 10.1016/j.ijcard.2013.07.115. View

2.
LaFleur J, McBeth C, Gunning K, Oderda L, Steinvoort C, Oderda G . Prevalence of drug-related problems and cost-savings opportunities in medicaid high utilizers identified by a pharmacist-run drug regimen review center. J Manag Care Pharm. 2007; 12(8):677-85. PMC: 10438027. DOI: 10.18553/jmcp.2006.12.8.677. View

3.
Khader M, Snouber S, Alkhatib A, Nazzal Z, Dudin A . Prevalence of patients with end-stage renal disease on dialysis in the West Bank, Palestine. Saudi J Kidney Dis Transpl. 2013; 24(4):832-7. DOI: 10.4103/1319-2442.113913. View

4.
Rama M, Viswanathan G, Acharya L, Attur R, Reddy P, Raghavan S . Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital. Indian J Pharm Sci. 2012; 74(1):63-8. PMC: 3507347. DOI: 10.4103/0250-474X.102545. View

5.
Mahmood M, Malone D, Skrepnek G, Abarca J, Armstrong E, Murphy J . Potential drug-drug interactions within Veterans Affairs medical centers. Am J Health Syst Pharm. 2007; 64(14):1500-5. DOI: 10.2146/ajhp060548. View